Clicky

Taysha Gene Therapies, Inc.(TSHA)

Description: Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.


Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Deficiency Lipid Storage Disorders Monogenic Gangliosidosis Monogenic Diseases Rett Syndrome Treatment Of Rett Syndrome

Home Page: www.tayshagtx.com

TSHA Technical Analysis

3000 Pegasus Park Drive
Dallas, TX 75247
United States
Phone: 214 612 0000


Officers

Name Title
Mr. R. A. Session II Founder, Pres, CEO & Director
Mr. Kamran Alam CPA, M.B.A. Chief Financial Officer
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M Chief Medical Officer and Head of R&D
Mr. Frederick Porter Ph.D. Chief Technical Officer
Mr. Jim Rouse Chief Information Officer
Ms. Tracy M. Porter Chief People Officer
Ms. Emily McGinnis M.P.H. Chief Patient Officer & Head of Gov. Affairs
Ms. Mishima Gerhart Chief Regulatory Officer & Head of Quality
Mr. Sean McAuliffe Chief Commercial Officer
Mr. Greg Gara Sr. VP of Manufacturing

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 13.3011
Price-to-Sales TTM: 0
IPO Date: 2020-09-24
Fiscal Year End: December
Full Time Employees: 178
Back to stocks